Find in Library

Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al

oleh: Zarir F. Udwadia, Hanmant Barkate, Saiprasad Patil, Shabbir Rangwala, Wen Wu, Cynthia F. Caracta, Monika Tandon